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3Abstract
Background:	Bacteroides	thetaiotaomicron	(Bt)	is	a	prominent	member	of	the	human	intestinal
microbiota	that,	like	all	Gram-negative	bacteria,	naturally	generates	nanosized	outer	membrane
vesicles	(OMVs)	which	bud	off	from	the	cell	surface.	Importantly,	OMVs	can	cross	the	intestinal
epithelial	barrier	to	mediate	microbe-host	cell	crosstalk	involving	both	epithelial	and	immune	cells	to
help	maintain	intestinal	homeostasis.	Here	we	have	examined	the	interaction	between	Bt	OMVs	and
blood	or	colonic	mucosa-derived	dendritic	cells	(DC)	from	healthy	individuals	and	patients	with
Crohn’s	disease	(CD)	or	ulcerative	colitis	(UC).
Results:	In	healthy	individuals,	Bt	OMVs	stimulated	significant	(p<0.05)	IL-10	expression	by	colonic
DC,	whereas	in	peripheral	blood-derived	DC	they	also	stimulated	significant	(p<0.001	and	p<0.01,
respectively)	expression	of	IL-6	and	the	activation	marker	CD80.	Conversely,	in	UC	Bt	OMVs	were
unable	to	elicit	IL-10	expression	by	colonic	DC.	There	were	also	reduced	numbers	of	CD103+	DC	in
the	colon	of	both	UC	and	CD	patients	compared	to	controls,	supporting	a	loss	of	regulatory	DC	in	both
diseases.	Furthermore,	in	CD	and	UC,	Bt	OMVs	elicited	a	significantly	lower	proportion	of	DC	which
expressed	IL-10	(p<0.01	and	p<0.001,	respectively)	in	blood	compared	to	controls.	These	alterations
in	DC	responses	to	Bt	OMVs	were	seen	in	patients	with	inactive	disease,	and	thus	are	indicative	of
intrinsic	defects	in	immune	responses	to	this	commensal	in	inflammatory	bowel	disease	(IBD).
Conclusions:	Overall,	our	findings	suggest	a	key	role	for	OMVs	generated	by	the	commensal	gut
bacterium	Bt	in	directing	a	balanced	immune	response	to	constituents	of	the	microbiota	locally	and
systemically	during	health	which	is	altered	in	IBD	patients.	
Introduction
The	human	gastrointestinal	(GI)	tract	contains	an	estimated	3.8	x	1013	bacteria	(1011/mL	contents)
that	play	an	essential	role	in	digestion,	pathogen	resistance	and	the	development	of	different	sensory
systems	within	the	GI	tract	including	the	immune	system1–3.	Gram-negative	Bacteroides
thetaiotaomicron	(Bt)	is	a	prominent	member	of	the	intestinal	microbiota	of	many	animals4–6.	Bt	has
important	functions	in	nutrient	absorption	and	promoting	barrier	function	via	its	effect	on	goblet	cell
development	and	mucus	secretion7,8.	In	addition,	Bt	has	been	described	to	be	both	protective	and
4pathogenic	in	rodent	models	of	intestinal	inflammation9–11.	Typical	of	all	Gram-negative	bacteria,	Bt
generates	nanosized	outer	membrane	vesicles	(OMVs)	during	its	normal	growth12,13.	The	content	of
OMVs	is	varied,	including	enzymes	and	hydrolases,	cell-wall	components	such	as	lipooligosaccharide
and	peptidoglycan,	nucleic	acids	and	metabolites14–16.	Importantly,	OMVs	are	packaged	within	a	lipid
bilayer	which	protects	them	from	physical,	chemical	and	biological	degradation	within	the	GI
tract17,18.
The	production	of	OMVs	by	pathogenic	Gram-negative	bacteria	including	Vibrio	cholerae,	Neisseria
meningitidis,	Helicobacter	pylori	and	Haemophilus	influenzae	plays	a	central	role	in	infection	and	the
delivery	of	toxins	to	host	cells,	and	stimulation	of	the	immune	system13,19–22.	OMVs	produced	by
commensal	bacterial	species	of	the	genus	Bacteroides	have	been	implicated	in	microbial	and	immune
homeostasis.	For	example,	polysaccharide	A	expressed	on	the	surface	of	OMVs	from	Bacteroides
fragilis	can	promote	both	regulatory	T	cell	responses	and	production	of	interleukin	(IL)-10	by	dendritic
cells	(DC)	in	a	TLR-2	and	Gadd45α-dependent	manner	that	contributes	to	protection	in	a	mouse
model	of	acute	colitis23.	Bt	produces	OMVs	containing	phosphatases	and	sulfatases	which	are
implicated	in	epithelial	intracellular	signalling	and	immunomodulatory	functions24,25.	In	fact,	OMVs
from	both	pathogenic	and	commensal	strains	have	been	used	in	vaccine	formulations,	supporting
their	role	in	microbe-host	immune	system	crosstalk26–29.
Most	of	our	understanding	of	OMVs-host	interactions	comes	from	animal	model	systems	with	the
human	immune	response	to	Bt	and	OMVs	being	poorly	characterised.	Therefore,	we	have	examined
how	DC	from	healthy	individuals	respond	to	Bt	OMVs	and	how	these	responses	change	in	individuals
with	inflammatory	bowel	disease	(IBD).	The	IBDs,	including	Crohn’s	disease	(CD)	and	ulcerative	colitis
(UC),	are	chronic,	relapsing-remitting	diseases	of	the	GI	tract	affecting	more	than	0.3%	of	western
populations30.	Both	CD	and	UC	are	characterised	by	destruction	of	the	mucosal	barrier	leading	to
inappropriate	responses	to	the	microbiota.	These	altered	responses	stem	from	changes	in	the
underlying	immune	system,	including	loss	of	key	populations	of	regulatory	innate	and	adaptive
5immune	cells	leading	to	overexuberant	pathogenic	T	cell	responses31–36.	These	changes	are	also
associated	with	intestinal	microbial	dysbiosis	characterised	by	reductions	in	Bacteroidetes	and
Firmicutes	with	concomitant	increase	in	Proteobacteria37.
IL-10	is	an	immunoregulatory	cytokine	and	is	essential	for	intestinal	homeostasis	as	demonstrated	in
mice	lacking	either	IL-10	or	IL-10	receptor	genes	that	spontaneously	develop	inflammatory
disease38,39.	IL-10	is	important	for	regulating	T	cell	responses	to	the	commensal	microbiota	and
largely	acts	via	the	innate	immune	system,	including	macrophages	and	DC40–42.	In	humans,	the
importance	of	the	IL-10	pathway	in	regulating	immune	response	is	clear	from	patients	with
monogenic	defects	in	IL10	and	IL10R	genes	that	develop	rapid	onset	IBD43–45.
DC	are	key	antigen-presenting	cells	which	both	produce	and	respond	to	IL-10	to	regulate	immune
responses42,46,	with	both	human	studies	and	mouse	models	demonstrating	their	central	role	in
immune	homeostasis	and	microbial	tolerance	47–50.	This,	together	with	the	alterations	to	DC	subsets
in	IBD	32–34,51,52,	led	us	to	hypothesize	that	DC	are	key	effectors	in	the	healthy	response	to	Bt	that	is
mediated	by	OMVs	and	that	DC	responses	to	Bt-derived	OMVs	may	be	altered	in	IBD.
Results
Bt	OMVs	elicit	production	of	immunoregulatory	IL-10	by	DCs	of	the	healthy	human	colon
During	normal	anaerobic	growth,	Bt	cells	produce	and	release	OMVs	into	the	external	milieu	which
consist	of	nanostructures	exhibiting	a	typical	spherical	lipid	bilayer	(Figure	1a)	53.	In	order	to	examine
mucosal	immune	responses	to	OMVs,	colonic	biopsies	from	healthy	individuals	(see	Table	3)	were
cultured	intact	in	a	polarised	in	vitro	culture	system	(pIVOC)	for	6	h	with	108-109	Bt	OMVs/mlor
medium	alone	added	to	the	apical	surface.	Immune	mediators	were	then	measured	in	tissue
homogenates.	Amongst	the	panel	of	13	cytokines/chemokines	tested	(see	Methods)	all	but	IFNα	were
induced	at	detectable	levels	though	TNF-α,	IL-17a,	IL-12p70	and	IL-23	were	very	low	(<5	pg/ml)
(Supplementary	Figure	1a).	Those	cytokines	significantly	upregulated	in	response	to	OMVs	were
chemoattractant	MCP-1	(CCL2)	(p<0.001),	IFN-γ	(p<0.01),	IL-8,	IL-1β,	IL-6	and	notably	IL-10	(all
p<0.05;	Figure	1b).
6To	determine	if	DC	were	a	source	of	cytokines	in	the	pIVOC	system,	total	lamina	propria	(LP)	cells
were	obtained	from	five	distal	and	five	proximal	colonic	biopsies	by	enzymatic	digestion	and	were
cultured	for	20	h	in	the	presence	of	either	non-viable	(freeze-killed)	Bt	(107	cfu/mL),	Bt	OMVs
(1010/mL)	or	medium	only.	DC	were	identified	as	HLA-DR+	cells	which	did	not	express	CD14	or	CD64,
markers	of	macrophages	or	monocytes	(Figure	1c).	The	majority	(>60%)	of	DC	expressed	CD11c,	a
marker	of	myeloid(m)	DC	and	were	activated	by	both	Bt	and	its	OMVs	as	shown	by	increased
expression	of	HLA-DR	(Figure	1d).	Further,	while	a	proportion	of	LP	mDC	expressed	IL-6	(5-10	%)	in
response	to	Bt	and	OMVs,	a	greater	and	significant	(p<0.05)	proportion	of	mDC	expressed	IL-10	in
response	to	either	Bt	or	Bt	OMVs	(10-30%)	compared	to	medium-only	control	cultures	(Figure	1e),
consistent	with	DC	being	a	source	of	IL-10	detected	in	intact	colonic	biopsies	(Figure	1b).	Importantly,
absolute	numbers	of	mDC	expressing	IL-10,	but	not	IL-6,	were	also	significantly	increased	(p<0.05)
after	culture	with	Bt	or	Bt	OMVs	compared	to	the	medium-only	condition	(Supplementary	Figure	1b).
Thus,	in	health,	IL-10	is	a	predominant	cytokine	produced	locally	by	DC	in	the	colon	in	response	to	Bt
and	Bt	OMVs.
Bt	and	Bt	OMVs	promote	protective	circulating	DC	responses
To	determine	whether	Bt	and	Bt	OMVs	elicited	a	similar	response	from	circulating	DC,	peripheral
blood	mononuclear	cells	(PBMC)	from	healthy	donors	were	stimulated	with	Bt	or	varying	doses	of	Bt
OMVs	for	20	h	and	DC	responses	were	examined	by	multiparameter	flow	cytometry.	DC	were
identified	within	PBMC	based	upon	the	absence	of	expression	of	lineage	specific	markers
(CD3/CD14/CD16/CD19/CD34)	and	being	HLA-DR+.	Within	this	population,	both	CD11c+	mDC	and
CD123+	plasmacytoid	(p)DC	were	identified	with	mDC	predominating	(Figure	2a).
To	examine	how	DC	responded	to	culture	with	Bt	and	Bt	OMVs,	expression	of	the	activation	marker
CD80	and	intracellular	cytokines	IL-6	and	IL-10	were	measured	by	flow	cytometry.	Results	are
displayed	as	percentages	of	total	mDC	and	pDC	staining	positively	for	these	markers.	Both	Bt	and	Bt
OMVs	activated	mDC	and	pDC	as	seen	by	expression	of	co-stimulatory	marker	CD80	on	the	majority
of	mDC	(60-80	%)	and	a	major	proportion	of	pDC	(40-50	%)	(Figure	2b).	However,	cytokine	responses
7were	predominated	by	mDC	with	30-60	%	expressing	IL-6	in	response	to	Bt	and	to	a	range	of
concentrations	of	Bt	OMVs	(Figure	2c)	while	only	small	proportion	of	pDC	(<10	%)	produced	IL-6	in
response	to	high	concentrations	of	Bt	OMVs	(Supplementary	Figure	2a	and	b).	Importantly,	IL-10	was
expressed	by	a	significant	(p<0.01)	proportion	of	mDC	(10-15	%)	in	response	to	both	Bt	and	a	range
of	Bt	OMV	concentrations	but	not	by	pDC	(Figure	2c	and	Supplementary	Figure	2a	and	b).	When	levels
of	cytokines	were	measured	in	culture	supernatants,	there	was	compared	to	control	cultures	a
significant	(p<0.01)	amount	of	IL-6	in	response	to	the	highest	concentration	of	Bt	OMVs	(109/mL),
while	IL-10	was	detected	in	response	to	Bt	OMVs	at	concentrations	of	³108/mL	(p<0.05)	(Figure	2d).
These	findings	suggest	that,	as	seen	with	mucosal	DC,	circulating	immune	responses	to	Bt	OMVs	in
healthy	individuals	involve	a	balance	of	protective	IL-6	and	regulatory	IL-10.
Reduced	IL-10	response	to	Bt	OMVs	and	associated	loss	of	CD103+	DC	in	IBD
CD	and	UC	are	characterised	by	a	loss	of	mucosal	barrier	integrity,	leading	to	translocation	of	bacteria
and	triggering	of	inappropriate	immune	responses.	Alterations	in	colonic	DC	populations,	including
loss	of	regulatory	CD103+	DC,	have	been	demonstrated	in	IBD33,34,49,50.	We	confirmed	these	findings
in	our	patient	cohort	(see	Table	1)	by	characterising	mDC	in	LP	cells	from	proximal	and	distal	colon	of
healthy	controls	(HC)	and	individuals	with	CD	and	UC,	including	expression	of	CD103	and	SIRPα	(a
myeloid	marker)	which	subdivides	mDC	into	SIRPα+	CD103-	(similar	to	monocyte-derived	DC),	SIRPα+
CD103+	(similar	to	CD1c+	cDC2)	and	SIRPα-CD103+	(similar	to	CD141+cDC1)	DC54–56.	Individuals
with	UC	and	CD	were	subdivided	into	active	(red	symbols)	or	inactive	(black	symbols)	disease	based
on	histological	findings	(Table	1)	and	blood	or	faecal	markers	of	inflammation	(Table	2).	Inactive
disease	was	defined	as	having	macroscopically	normal	mucosa	from	rectum	to	terminal	ileum	(TI)
from	colonoscopy	and/or	not	having	inflammatory	markers	in	blood	and	faeces	at	time	of	sampling.
Absolute	numbers	of	mDC	were	unchanged	in	IBD	compared	to	HC,	regardless	of	disease	activity
(Supplementary	Figure	3a).	Total	CD103+	mDC	were	also	only	significantly	reduced	(p<0.05)	in	the
proximal	colon	of	CD	patients	(Supplementary	Figure	3b)	and	specifically	those	with	active	disease
8trended	towards	significance	(p=	0.0562)Further,	when	CD103+	mDC	were	subdivided	based	on
expression	of	SIRPα,	both	SIRPα+	CD103+	and	SIRPα-CD103+	DC	were	significantly	reduced	(p<0.05;
p<0.05)	in	the	proximal	colon	of	all	CD	patients,	along	with	SIRPα-CD103+DC	being	substantially
reduced	(p=0.0512)	in	the	distal	colon	of	all	UC	patients	compared	to	HC	(Supplementary	Figure	3c,
top	and	middle	panels).	However,	when	UC	and	CD	patients	were	subdivided	based	on	disease
activity,	only	CD	patients	with	active	disease	had	substantial	reductions	(p=0.0885)	in	SIRPα+
CD103+	DC	and	significant	reductions	(p<0.05)	in	SIRPα-CD103+	DC.	The	numbers	of	SIRPα+	CD103-
DC	in	either	the	proximal	or	distal	colon	of	UC	and	CD	patients	was	not	different	to	HC
(Supplementary	Figure	3c;	bottom	panels)	and	this	held	true	when	patients	were	subdivided	based	on
disease	activity.	Thus,	both	CD	and	UC	are	characterised	by	loss	of	CD103+	DC	in	the	colonic	LP	and
in	CD	the	loss	of	CD103+	DC	occurred	in	individuals	with	active	disease.
Having	confirmed	alterations	in	DC	populations	in	IBD	patients	we	next	investigated	if	the	immune
response	to	Bt	OMVs	was	also	altered	in	IBD	patients.	To	this	end,	total	LP	cells	from	distal	and
proximal	colon	of	UC	patients	(all	with	mild	active	(Mayo	1)	disease	as	defined	by	histological	findings
(Table	1)	and	blood/faecal	inflammatory	markers	(Table	2)	were	stimulated	for	20	h	with	1010	Bt
OMV/mL	or	medium	only	and	intracellular	cytokine	expression	by	DC	was	examined.	Unlike	in	HC,	Bt
OMVs	did	not	stimulate	a	significant	proportion	of	mDC	from	LP	of	UC	patients	to	express	IL-6	or	IL-10
(Figure	3a).	Likewise,	despite	similar	numbers	of	total	mDC	in	UC	and	HC,	absolute	numbers	of	IL-6-
or	IL-10-expressing	mDC	were	not	increased	by	Bt	OMVs	in	UC	(Supplementary	Figure	4a	and	b)	There
was	a	non-significant	trend	towards	reduced	proportions	and	absolute	numbers	of	mDC	expressing
both	IL-6	and	IL-10	in	UC	compared	to	HC	(Figure	3band	Supplementary	Figure	4c).	Thus,	these
findings	suggest	a	loss	of	immunoregulatory	DC	response	to	Bt	OMVs	in	UC	which	may	in	part	be
explained	by	the	reduction	in	immunoregulatory	CD103+	DC	in	these	patients	(Supplementary	Figure
3).
Circulating	DC	IL-10	response	to	Bt	OMVs	is	also	reduced	in	both	UC	and	CD
9To	assess	whether	changes	in	colonic	DC	and	response	to	Bt	OMVs	in	IBD	were	reflected	systemically
in	individuals	with	CD	or	UC,	PBMC	were	used	to	examine	circulating	DC	responses.	In	these
experiments,	disease	activity	was	determined	for	UC	and	CD	patients	using	both	macroscopic
histological	findings	from	colonoscopy	(Table	1)	and	blood	or	faecal	markers	of	inflammation	(Table
2).	Inactive	disease	was	defined	as	having	macroscopically	normal	mucosa	from	rectum	to	terminal
ileum	(TI)	from	colonoscopy	and/or	not	having	inflammatory	markers	in	blood	and	faeces	at	time	of
sampling.
As	in	Figure	2a,	mDC	were	identified	in	PBMC	as	CD11c+HLA-DR+	lineage	marker	(CD3/14/16/19/34)
negative	cells.	To	examine	how	mDC	responded	to	culture	with	Bt	and	Bt	OMVs,	expression	of
intracellular	cytokines	IL-6	and	IL-10	were	measured	by	flow	cytometry.	Results	are	displayed	as
percentages	of	total	mDC	staining	positively	for	these	markers.	Following	20	h	culture,	a	significant
proportion	of	mDC	expressed	IL-6	in	response	to	both	Bt	and	high	doses	of	Bt	OMVs	in	both	inactive
UC	(≥109	OMVs/mL)	or	inactive	CD	(≥109	OMVs/mL)	patients,	which	was	comparable	to	the	response
of	mDC	from	HC	(Figure	4a).	However,	neither	Bt	nor	OMVs	induced	significant	expression	of	IL-10	by
mDC	in	inactive	UC	patients	and	the	proportion	of	mDC	that	expressed	IL-10	was	significantly	lower
(p<0.001;	p<0.05)	than	that	of	HC	at	high	doses	of	OMVs	(≥109	OMVs/mL)	(Figure	4b).	In	patients
with	inactive	CD,	a	low	but	significant	(p<0.05)	proportion	of	mDC	(10	%)	expressed	IL-10	in	response
to	the	highest	dose	of	OMVs	(1010/mL)	but	at	109/mL	Bt	OMVs	the	proportion	of	mDC	expressing	IL-10
was	significantly	(p<0.01)	reduced	compared	to	HC	(Figure	4c).	Interestingly,	when	DC	responses	to
Bt	and	Bt	OMVs	were	examined	in	UC	patients	with	active	disease,	the	proportion	of	IL-10	expressing
mDC	was	comparable	to	that	of	healthy	controls	(Figure	4d),	suggesting	intrinsic	alterations	in	the
immune	system	rather	than	inflammation	drives	the	loss	of	regulatory	response	to	Bt	OMV	in	UC.
Specificity	of	DC	cytokine	response	to	commensal	bacteria
To	determine	if	altered	responses	existed	to	bacteria	other	than	Bt	in	individuals	with	UC,	circulating
DC	responses	to	a	selection	of	19	additional	human	intestinal	commensal	bacteria	were	examined,
including	several	Gram-negative	species.	As	in	previous	experiments,	disease	activity	was	determined
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for	UC	patients	using	both	macroscopic	histological	findings	from	colonoscopy	(Table	1)	and	blood	or
faecal	markers	of	inflammation	(Table	2).	Inactive	disease	was	defined	as	having	macroscopically
normal	mucosa	from	rectum	to	TI	from	colonoscopy	and/or	not	having	inflammatory	markers	in	blood
and	faeces	at	time	of	sampling.	For	UC	patients	with	inactive	disease	the	proportion	of	mDC
expressing	IL-10	in	PBMC	in	response	to	each	of	the	19	bacteria	tested	was	comparable	to	HC	(Figure
5a).
We	additionally	examined	circulating	DC	responses	to	a	Gram-negative	commensal	of	the	human
respiratory	tract,	Prevotella	nanceiensis	(Pn),	and	its	OMVs57.	Pn,	closely	related	to	Bt,	exhibits	weak
inflammatory	properties	indicating	that	it	is	tolerated	by	the	respiratory	immune	system57,58.	In
response	to	non-viable	(freeze-killed)	Pn,	a	proportion	of	mDC	derived	from	PBMC	of	healthy	donors
expressed	both	IL-6	(40-50	%)	and	IL-10	(10	%)	(Figure	5b).	However,	in	contrast	to	the	response	to
Bt	OMVs	(Figure	2b),	the	majority	(³80	%)	of	mDC	did	not	express	either	IL-6	or	IL-10	in	response	to
Pn	OMVs	even	at	the	highest	dose	of	109	OMV/mL	(Figure	5b).
Further,	in	inactive	UC	patients,	the	proportion	of	mDC	expressing	IL-6	or	IL-10	in	response	to	Pn
OMVs	was	comparable	to	HC	with	only	IL-10	being	reduced	in	response	to	Pn	(Figure	5c).	This
suggests	that	the	circulating	DC	IL-10	response	elicited	by	Bt	OMVs	in	HC	may	be	restricted	to	specific
members	of	the	microbiota,	with	the	reduced	IL-10	response	in	inactive	UC	also	potentially	being
specific	to	Bt	OMVs.
Discussion
Despite	Bt	being	extensively	used	as	a	model	organism	to	study	host	immune-microbiota
interactions59,	the	nature	of	the	immune	response	to	Bt	in	humans	is	poorly	characterised.	Here	we
present	novel	data	showing	that	the	response	of	intestinal	mucosal	cells	to	Bt	involves	a	balance	in
the	production	of	protective	IL-6	and	regulatory	IL-10	to	which	DC	both	locally	and	systemically
contribute.	Furthermore,	this	balanced	response	is	mediated	by	OMVs,	nanosized	vesicles	produced
by	the	bacteria	which	are	known	to	cross	the	mucus	layer	of	the	intestine	to	directly	interact	with
immune	cells	beneath	the	boundary	epithelium60.	Furthermore,	we	show	that	in	individuals	with	CD
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and	UC	there	is	a	loss	of	regulatory	IL-10	response	to	Bt	OMVs	by	blood-derived	DC,	while	protective
IL-6	responses	are	retained.	In	UC	there	is	also	a	lack	of	colonic	DC	IL-10	response	to	Bt	OMVs	and
this	accompanies	a	pronounced	loss	of	immunoregulatory	CD103+	DC	in	the	colonic	LP.	Importantly,
the	altered	circulating	DC	response	to	Bt	OMVs	is	only	seen	in	UC	and	CD	patients	with	inactive
disease,	which	suggests	that	underlying	defects	in	the	immune	system	rather	than	inflammation	drive
these	responses.	IL-6	was	significantly	induced	by	Bt	OMVs	in	healthy	individuals	both	in	whole
colonic	biopsy	cultures	as	well	as	in	blood	DC.	IL-6	is	a	pleiotropic	cytokine	produced	by	innate
immune	cells	like	DC	in	response	to	TLR	stimulation.	It	has	essential	roles	in	driving	B	cell
differentiation	and	antibody	production	as	well	as	maintaining	balanced	CD4+	T	helper	responses	by
promoting	Th17/Tfh	cells	and	inhibiting	regulatory	T	cells61.	However,	aberrant	IL-6	responses	are
implicated	in	the	pathogenesis	of	inflammatory	diseases	including	Crohn’s	disease	and	ulcerative
colitis	and	blockade	of	IL-6	is	protective	in	murine	colitis62–64.	Therefore,	it	is	not	surprising	that	we
found	an	intact	IL-6	response	to	Bt	OMVs	in	CD	and	UC	comparable	to	HC	specifically	in	the	periphery.
However,	in	HC	this	was	critically	balanced	by	a	significant	IL-10	response	which	is	known	to	directly
inhibit	IL-6-mediated	responses65–67.	In	fact,	we	have	shown	that	both	CD	and	UC	are	characterised
by	heightened	memory	B	cell	and	antibody	responses	to	the	commensal	microbiota	and	a	lack	of	IL-
10-mediated	suppression	of	IL-6	may	directly	contribute	to	this	skewed	B	cell	response36.	Further,	in
colonic	LP	of	UC	patients,	there	was	a	clear	lack	of	IL-6	and	IL-10	production	by	DC	to	Bt	OMVs
suggesting	a	non-responsive	phenotype	which	may	contribute	to	a	loss	of	colonic	resident	memory	T
cells	in	these	patients35,36.	Thus,	a	deficient	mucosal	DC	response	to	Bt	OMVs,	possibly	due	to	loss	of
key	populations	of	CD103+	DC	and	resident	memory	T	cells,	could	lead	to	poorly	regulated	systemic
responses	and	pathology.
The	marked	DC	IL-10	response	to	Bt	OMV	may	be	specific	as	we	did	not	see	this	response	to	OMVs
generated	by	the	closely	related	human	lung	commensal	Pn	despite	a	comparable	IL-10	response	to
the	whole	bacterium.	This	may	be	related	to	regional,	tissue	and	mucosa	specific	differences	in
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addition	to	differences	in	OMV	cargo	and	specific	antigens	able	to	elicit	the	IL-10	response	by	DC	that
are	restricted	to	or	are	only	accessible	in	Bt	OMVs.	An	example	of	such	species-specific	expression	of
immunomodulatory	molecules	is	the	capsular	polysaccharide	A	(PSA)	antigen	expressed	by	the
closely	related	commensal	species	Bacteroides	fragilis	(Bf).	The	PSA	antigen	is	expressed	in	Bf	OMVs
and	elicits	IL-10	production	from	DC	in	a	TLR-2-dependent	manner23.	The	immunomodulatory	effect	of
Bt	may	also	not	be	restricted	to	immune	cells	and	DC.	In	the	immortalised	human	colonic	epithelial
cell	line	Caco-2,	Bt	stimulates	nuclear	export	of	the	NFkB	subunit	RelA	in	a	mechanism	involving
PPARγ,	which	in	turn	dampens	inflammatory	responses9.	PPARγ-mediated	anti-inflammatory	functions
are	well-recognized	and	agonists	are	being	explored	in	the	treatment	of	UC68.	Bt	has	also	been	shown
to	contain	a	pyrin-like	protein	(PLP)	which	in	Caco-2	cells	dampens	the	NFkB	pathways11.	Although
neither	PLP	nor	stimulation	of	PPARγ	has	been	linked	to	Bt	OMVs	directly,	it	is	compatible	with	its
potential	immunomodulatory	properties.	The	NFkB	pathways	are	directly	involved	in	transcriptional
regulation	of	both	IL-6	and	IL-10	downstream	of	TLR	stimulation62,67	and	Bt	OMVs	may	act	via	these
pathways	to	control	expression	of	these	cytokines	from	DC.	Future	work	to	characterise	the	contents
of	the	OMVs	will	be	necessary	to	determine	mechanisms	of	action	on	DC	in	health	or	IBD.
The	importance	of	regulatory	IL-10	to	the	healthy	response	of	DC	to	Bt	OMVs	is	congruent	with
observations	in	mice	showing	that	Bt	is	colitogenic	in	dnKO	mice	lacking	IL-10	and	TGFb-signalling
pathways10,24.	Conversely,	a	strain	of	Bt	different	to	that	used	in	our	study	was	shown	to	protect
otherwise	susceptible	IL-10R-deficient	mice	or	dextran	sodium	sulfate-treated	mice	and	rats	from
developing	colitis11.	These	discrepancies	support	the	proposal	that	Bt	protective	functions	are,	at
least	in	mice,	not	limited	to	IL-10-related	pathways	and	may	be	dependent	on	environmental,
bacterial	strain-	and	host-specific	factors69.	Likewise	in	humans,	Bt	OMVs	could	elicit
immunomodulatory	functions	via	different	mechanisms	in	addition	to	their	role	in	directing	balanced
DC	responses	that	could	change	in	inflammatory	settings	such	as	in	IBD.	A	recent	study	has
demonstrated	a	key	role	for	IL-10R	signalling	in	DC	in	controlling	aberrant	Th1	responses	both	via
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inhibition	of	IL-1b	and	IL-12	in	paediatric	IBD	and	in	an	individual	with	IL10RA	gene	deficiency70.	This
fits	with	previous	reports	that	IL-10	is	both	produced	by	and	acts	via	DC	to	regulate	intestinal
inflammation42.	In	active	UC,	there	was	no	loss	of	IL-10	expression	by	circulating	mDC	in	response	to
Bt	OMVs;	however,	it	would	have	been	of	interest	to	additionally	determine	if	IL-10	was	able	to	inhibit
downstream	Th1	or	Th17	type	responses,	characteristic	of	IBD71,72.	Especially	given	the	essential	role
IL-6	plays	in	driving	inflammatory	T	cell	responses	and	antibody	production,	Bt	OMV-mediated
induction	of	regulatory	IL-	10	may	not	be	effective	at	dampening	these	responses	in	the	context	of
inflammation.	Likewise,	it	is	possible	that	the	normal	IL-10	response	in	active	UC	is	a	result	of	DC	or
other	cell	types	such	as	T	or	B	cells	having	lower	IL-10R	expression	or	impaired	pathway	function
leading	to	a	positive	feedback	loop	to	produce	more	IL-10.
Unlike	whole	bacteria,	OMVs	can	cross	from	the	lumen	of	the	intestine	through	the	epithelial	barrier
and	access	organs	and	tissues	beyond	the	GI	tract17,60.	Exploiting	this	property	of	OMV,	Bt	has	been
successfully	engineered	to	generate	OMVs	containing	both	therapeutic	proteins	and	vaccine	antigens
for	treating	mucosal	inflammation	and	generating	protective	mucosal	and	systemic	immunity28,29.
Thus,	Bt	OMVs	have	considerable	therapeutic	potential.	The	fact	that	circulating	DC	responses	to	Bt
and	their	OMVs	largely	reflect	the	local	colonic	DC	response	in	health	and	in	disease	is	interesting	on
several	levels.	Firstly,	if	intestinal	disease	activity	can	be	assessed	using	a	readout	from	the	blood,
this	avoids	the	necessity	for	taking	additional	biopsies	during	colonoscopy.	Secondly,	the	reduced	IL-
10	response	to	Bt	OMVs	in	inactive	UC	was	unique	and	could	not	be	recapitulated	in	response	to
another	related	Gram-negative	commensal,	Pn.	Thus,	Bt	OMVs	might	be	of	use	in	highlighting	an
immune	signature	specific	to	UC	that	is	detectable	in	blood	samples.	Finally,	active	inflammation
appears	to	mask	the	underlying	defects	in	DC	interplay	with	Bt	OMVs,	leading	to	a	health-associated
circulating	DC	response.	However,	we	did	not	fully	explore	all	possible	cytokines	or	pathways	elicited
by	Bt	OMVs	and	it	is	possible	that	in	active	IBD	the	signature	may	be	distinct	and	different	from
health.	For	instance,	Bt	has	been	shown	to	elicit	IL-8	from	paediatric	CD	biopsies	but	not	from	healthy
controls73.	Additionally,	reduced	IL10RA	expression	and	reduced	responsiveness	occur	in	a	subgroup
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of	more	severe	paediatric	IBD	patients	and	these	are	associated	with	enhanced	IL-1b	expression70.	It
will	in	future	studies	be	important	to	identify	the	specific	factor	or	factors	present	in	Bt	OMVs	that
trigger	a	healthy	immune	response	to	realise	their	potential	use	as	a	novel	therapy	for	IBD.
Conclusions
Homeostatic	and	regulatory	immune	responses	are	generated	to	commensal	bacteria	both	locally	and
systemically.	For	Bt,	these	responses	involve	a	balance	of	host	protective	IL-6	and	regulatory	IL-10
produced	by	DC.	Importantly,	OMVs	produced	by	Bt	are	instrumental	in	eliciting	this	appropriate
response	both	in	the	colonic	mucosa	and	in	the	blood.	In	patients	with	UC	and	CD,	there	is	a	loss	of
regulatory	IL-10	response	by	DC	to	Bt	OMVs	which	may	contribute	to	the	inflammatory	milieu	of	the
intestine	and	systemically	in	these	diseases.
Methods
Study	design	and	sampling
The	aim	of	this	study	was	to	characterise	the	human	DC	response	to	Bt	OMVs	and	determine	whether
it	is	altered	in	IBD.	Healthy	donors	(age	17-86)	undergoing	investigative	colonoscopy	and	individuals
diagnosed	with	CD	(age	21-80)	and	UC	(age	24-70)	were	recruited	from	outpatient	clinics	at	St	Marks
Hospital,	London	North	West	University	Healthcare	NHS	Trust.	Clinical	characteristics	of	patients	and
controls	are	in	Tables	1	and	2.	Active	disease	for	CD	and	UC	was	defined	as	having	macroscopic
inflammation	(rated	from	mild	(1)	to	severe	(3);	see	Table	1)	from	colonoscopy	findings	and/or
presence	of	blood	inflammatory	markers	C-reactive	protein	(CRP)	>5	and	erythrocyte	sedimentation
rate	(ESR)	between	1	and	20	or	faecal	calprotectin	>55	(See	Table	2).	Inactive	disease	was	defined	as
no	inflammation	from	rectum	to	terminal	ileum	(TI)	according	to	colonoscopy	findings	and/or	no	more
than	one	marker	of	inflammation	in	blood	(CRP	>5	or	ESR	between	1	and	20)	and	normal	faecal
calprotectin	(<55).
Patients	were	recruited	over	a	fixed	period	determined	by	ethical	permission,	and	no	data	were
excluded	at	the	end	of	the	study.	Additional	healthy	blood	volunteers	were	recruited	from	hospital
staff	and	visitors.	Ethics	approval	was	obtained	from	the	Health	Research	Authority	UK	and	London
Brent	Research	Ethics	Committee.	Written	informed	consent	was	received	from	participants	prior	to
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inclusion	in	the	study.
For	whole	biopsy	culture	experiments,	healthy	donors	were	recruited	from	endoscopy	clinics	at
Norfolk	and	Norwich	University	Hospital	following	informed	consent	(see	Table	3	for	demographics
data).	Ethics	approval	was	obtained	from	the	University	of	East	Anglia	Faculty	of	Medicine	and	Heath
Sciences	Ethics	Committee	and	Human	Tissue	Act	Subcommittee	ref	20152016-39HT	and	the	Norfolk
and	Norwich	University	Hospital	Research	and	Development	Committee	ref	20-01-16.
Preparation	of	bacteria	stocks
Bacteroides	thetaiotaomicron	VPI-5482	(Bt)	(DSMZ	2079)	and	Prevotella	nanciensis	(Pn)	(DSMZ
19126)	(both	from	DSMZ-German	Collection	of	Microorganisms	and	Cell	Cultures	GmbH,
Braunschweig,	Germany)	were	grown	under	anaerobic	conditions	at	37	°C	in	brain	heart	infusion	(BHI)
medium	(Oxoid/Thermo	Fisher,	Basingstoke,	UK)	supplemented	with	0.5	mg/L	haemin	(Sigma-Aldrich,
St	Louis,	MO,	USA)	(BHI–haemin).	Aliquots	(1	mL)	were	centrifuged	(13,000	rpm	for	10	min),
supernatants	removed	and	cell	pellets	were	killed	by	snap-freezing	before	storage	at	-80	°C.	Pellets
were	resuspended	in	phosphate-buffered	saline	(PBS)	for	use.	Other	commensal	bacteria	were
isolated	from	the	caecum	of	healthy	donors	with	the	exception	of	Collinsella	aerofaciens,	which	was
from	faeces74–76.	Strains	were	grown	anaerobically	in	Hungate	tubes	containing	Wilkins-Chalgren
broth	at	37	°C	for	24	h.	Cell	pellets	were	killed	by	snap-freezing	at	-80	°C	and	enumerated	by	flow
cytometry	following	SYBR	Green	staining.
Preparation	of	bacterial	OMVs
The	isolation	of	bacterial	vesicles	was	done	as	previously	described25.	Briefly,	Bt	or	Pn	were	grown
under	anaerobic	conditions	at	37	°C	in	an	anaerobic	cabinet.	Bacterial	starter-cultures	were	grown
overnight	in	20	mL	BHI	medium	supplemented	with	15	µM	haemin	(Sigma-Aldrich)	(BHIH).	An	aliquot
(0.5	mL)	of	the	starter-culture	was	used	to	inoculate	500	mL	BHI	supplemented	with	0.75	µM	haemin.
Cells	were	harvested	after	16	h	at	an	approximate	OD	(600	nm)	of	4.0.	The	cells	were	centrifuged	at
5500	g	for	45	min	at	4	°C	and	the	supernatants	filtered	through	polyethersulfone	(PES)	membranes
(0.22	μm	pore-size)	(Sartorius)	to	remove	debris	and	cells.	Supernatants	were	concentrated	by
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ultrafiltration	(100	kDa	molecular	weight	cut-off,	Vivaspin	50R,	Sartorius),	the	retentate	was	rinsed
once	with	500	mL	of	PBS	(pH	7.4)	and	concentrated	to	0.5	mL.
Further	purification	was	performed	by	fractionation	of	the	OMV	suspension	by	size-exclusion
chromatography	using	a	CL2-B	sepharose	(Sigma-Aldrich)	column	(120	cm	x	1	cm)	in	PBS.	The
absorbance	of	the	fractions	was	measured	at	280	nm	and	the	first	fractions	displaying	an	absorbance
peak	were	pooled	and	concentrated	down	to	1	mL	with	a	Vivaspin	20	centrifugal	concentrator	(100
kDa	molecular	weight	cut-off,	Sartorius)	and	filtered	through	a	0.22	µm	PES	membrane	(Sartorius).
Concentration	of	vesicles	was	determined	using	nanoparticle	tracking	analysis	as	described
previously29.	Bt	OMVs	were	at	1011	vesicles/mL	of	PBS	and	Pn	OMVs	were	at	2	x1010	vesicles/mL	of
PBS.
Transmission	Electron	Microscopy
Bt	OMVs	were	observed	using	negative	staining	with	transmission	electron	microscopy	(TEM)	as
previously	described53.	Briefly,	isolated	Bt	OMVs	were	adsorbed	to	carbon–formvar-coated	copper	EM
grids	(Agar	Scientific)	for	1	min	before	wicking	off	with	filter	paper	and	negatively	staining	with	2%
uranyl	acetate	solution	(BDH)	in	water	for	1	min.	Grids	were	air-dried	before	analysis	using	a	Tecnai
G2	20	Twin	TEM	(FEI)	at	29,000×	magnification.
Polarised	in	vitro	organ	culture	of	colonic	biopsies
Colonic	biopsies	were	taken	from	the	rectosigmoid	junction	(around	18	cm	from	rectum)	of
macroscopically	normal	patients	following	informed	consent.	The	polarised	in	vitro	culture	(pIVOC)	of
colonic	biopsies	used	was	adapted	from	a	previous	study77.	Briefly,	five	colonic	biopsies	were
collected	in	IVOC	medium	(Dulbecco’s	Modified	Eagle’s	Medium	(Sigma-Aldrich)	(45	%)	and	distilled
water	(45	%)	containing	0.47	g	NCTC-135	(Sigma-Aldrich),	0.11	g	sodium	bicarbonate	(Sigma-Aldrich),
and	10	%	newborn	calf	serum	(NCS,	Sigma-Aldrich).	Each	biopsy	was	orientated	with	the	mucosal	side
uppermost	on	a	cellulose	nitrate	filter	within	a	snapwell	support	and	mounted	within	a	well	of	a	six-
well	plate	containing	3	mL	of	IVOC	medium.	Once	mounted,	200	uL	of	IVOC	medium	was	added
apically	with	or	without	108-109	Bt	OMVs/ml.	The	plate	was	incubated	on	a	rotor	(12	rpm)	at	37	°C	for
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6	h,	after	which	the	biopsy	was	removed	intact	from	each	support,	flash-frozen	in	liquid	nitrogen	and
stored	at	-80	°C	for	later	protein	extraction	and	cytokine	analysis.
Biopsy	tissue	lysate	extraction
Biopsies	were	thawed	on	ice	and	a	mixture	of	122ul	CellLytic	MT	(Sigma	C3228)	and	3ul	protease
inhibitor	cocktail	(Sigma	P2714-1BTL)	was	added	with	5	acid-washed	glass	beads	(3mm	diameter).
Homogenisation	was	performed	using	a	MP	Biomedical	Fastprep-24	instrument	(Fisher	Scientific)	at
4m/s	for	30	seconds.	Samples	were	centrifuged	at	10,000rpm	at	4°	C	for	2	min.	The	tissue	lysate	was
then	transferred	to	a	1.5ml	pre-cooled	tube	and	centrifuged	at	10,000rpm	for	10min	at	4°	C.	The
supernatant	was	carefully	removed	and	stored	at	-80°	C	until	use	for	cytokine	bead	array	(see	below).
Isolation	of	colonic	lamina	propria	cells
Five	proximal	and	five	distal	colon	biopsies	(10	mg	tissue	each)	were	obtained	from	macroscopically
non‐lesional	tissue	sites	at	routine	colonoscopy	in	all	patients	as	previously	described55.	Biopsies
were	washed	in	HBSS	containing	1	mM	DTT	and	1	mM	EDTA	in	a	shaking	incubator	at	37	°C	for	30	min
to	remove	the	epithelial	layer.	Supernatants	were	discarded	and	wash	was	repeated	for	a	second	30
min	with	HBSS/DTT/EDTA.	Following	discard	of	supernatants,	biopsies	were	further	digested	in	RPMI
medium	containing	collagenase	D	(1	mg/mL)	and	Liberase	TL	(0.1	mg/mL)	for	1	h	shaking	at	37	°C	to
release	the	lamina	propria	(LP)	cells.	LP	cells	were	then	filtered	through	a	100	µM	strainer,	washed
with	PBS	and	centrifuged	at	600	g	for	5	min	before	proceeding	to	either	culture	or	FACS	staining.
Isolation	of	peripheral	blood	mononuclear	cells	(PBMC)
Blood	obtained	by	venepuncture	was	diluted	1:1	(vol:vol)	in	PBS	and	layered	over	Ficoll-Paque	Plus
(Amersham	Biosciences,	Chalfont	St.	Giles,	UK).	After	centrifugation	at	800	g	for	30	min	at	18	°C,
PBMC	were	collected	at	the	interface.	PBMC	were	resuspended	in	complete	medium	(Dutch	modified
RPMI	1640	(Sigma-Aldrich,	Dorset,	UK)	containing	100	U/mL	penicillin/streptomycin,	2	mM	L-
glutamine,	50	μg/mL	gentamicin	(Sigma-Aldrich)	and	10%	faetal	calf	serum	(TCS	cell	works,
Buckingham,	UK))	for	culture	or	in	PBS	for	FACS	analysis.
Bacterial	stimulation	of	blood	DC	or	LP	cells
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Per	condition,	5	x105	PBMC	were	plated	in	96-well	U-bottom	plates.	PBMC	were	incubated	with	either
106/mL	freeze-killed	commensal	bacteria	or	OMVs	at	10-fold	incremental	concentrations	from	1010	to
10	OMVs/mL	at	37	°C,	5	%	CO2	for	20	h.	LP	cells	were	isolated	as	described	above	and	resuspended	in
complete	medium	as	described	for	PBMC.	LP	cells	(1-2	x	105	per	condition)	were	plated	in	96-well	U-
bottomed	plates.	LP	cells	were	incubated	with	either	107/mL	freeze-killed	Bt,	1010/mL	of	Bt	OMVs	or
complete	medium	only	at	37	°C,	5	%	CO2	for	20	h.	For	intracellular	cytokine	responses,	2	µM
monensin	(Biolegend)	was	added	to	wells	during	incubation.	
Surface	marker	and	intracellular	cytokine	profiling	of	DC
Following	incubation,	PBMC	and	LP	cells	were	washed	with	PBS	and	viability	was	determined	by
labelling	cells	with	LIVE/DEAD™	Fixable	Near-IR	Dead	Cell	Stain	Kit	(ThermoFischer	Scientific)
according	to	the	manufacturer’s	instructions.	Cells	were	washed	with	FACS	Buffer	(1x	PBS	containing
2	%	FCS,	1	mM	ETDA	and	0.02	%	sodium	azide)	and	then	labelled	with	antibodies	to	identify	the
dendritic	cells	(Table	4).	Cells	were	fixed	in	1	%	paraformaldehyde	(PFA)	if	only	surface	markers	were
examined.
For	intracellular	cytokine	analysis,	cells	were	fixed	using	Leucoperm	A	buffer	(Bio-Rad)	and
permeabilised	using	Leucoperm	B	(Bio-Rad)	and	then	labelled	with	antibodies	to	interleukin	(IL)-10
and	IL-6	(Table	4).	Finally,	cells	were	fixed	again	in	1	%	PFA	and	stored	at	4°C.
Flow	cytometry
Single	cell	suspensions	were	acquired	on	the	BD	FACSCanto	II	(BD	Biosciences)	or	the	BD	LSR
Fortessa	(BD	Biosciences).	Compensation	was	carried	out	on	FACS	Diva	software	using	Anti-Mouse	Ig,
κ/Negative	Control	Compensation	Particles	Set	(BD	Biosciences)	conjugated	to	antibodies	used	in
above	labelling	experiments.	The	ArC™	Amine	Reactive	Compensation	Bead	Kit	(ThermoFischer
Scientific)	was	used	for	compensation	of	the	LIVE/DEAD™	Fixable	Near-IR	Dead	Cell	Stain	according	to
kit	instructions.	Data	analysis	was	done	using	FlowJo_v.10	software.
Cytokine	bead	array
The	LEGENDplex	Human	Inflammation	Panel	I	(Biolegend,	London,	UK	)	was	used	to	simultaneously
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quantify	13	human	cytokines/chemokines	(IL-1β,	IFN-α2,	IFN-γ,	TNF-α,	MCP-1	(CCL2),	IL-6,	IL-8
(CXCL8),	IL-10,	IL-12p70,	IL-17A,	IL-18,	IL-23,	and	IL-33)	in	biopsy	tissue	lysates	according	to	the
manufacturer’s	instructions	and	analysed	on	a	BD	LSR	Fortessa	using	the	PE	and	APC	channels.	Data
were	analysed	using	the	LEGENDplex	data	analysis	software	(Biolegend,	London,	UK).	All
cytokines/chemokines	were	detectable	apart	from	IFN-α2	which	was	below	detection	limits.
ELISA
PBMC	were	cultured	with	Bt	or	Bt	OMVs	as	described	above	and	cell	supernatants	were	taken	at	20	h
post-stimulation	and	stored	at	-80	°C.	Amounts	of	cytokines	(IL-6	and	IL-10)	were	measured	using
Human	DuoSet	ELISA	kits	(R	and	D	systems)	according	to	the	manufacturer’s	instructions.	Plates	were
read	on	the	Tecan	Infinite	F50	plate	reader	and	data	were	analysed	using	MagellanTM	software	(Tecan
Group	Ltd,	Mannedorf,	Switzerland).
Statistical	analysis
Statistical	analysis	was	carried	out	using	GraphPad	Prism	software	version	8.	For	in	vitro	experiments,
data	were	analysed	using	nonparametric	Mann	Whitney	U-tests	(Figure	1b	and	Supplementary	Figure
1a);	unpaired	t-tests	(Figure	3);	ordinary	one-way	ANOVA	with	Dunnett’s	multiple	comparisons	test
(Figure	1D,	Figure	2B	and	D	(IL-10),	Figure	5B	and	Supplementary	Figure	2B),	one-way	ANOVA	with
Brown-Forsyth	and	Welch	corrections	for	unequal	variance	with	Dunnett’s	T3	multiple	comparisons
test	(Figure	2C	and	Figure	4A	and	B)	or	non-parametric	Kruskal	Wallis	ANOVA	with	Dunn’s	multiple
comparisons	test	(Figure	1E,	Figure	2D	(IL-6)	and	Figure	4C)	when	making	comparisons	between
experimental	conditions	within	single	group;	or	ordinary	two-way	ANOVA	with	Holm’s	Sidak’s	multiple
comparisons	test	(Figures	4	and	5)	for	making	comparisons	between	groups	for	different	experimental
conditions.	Colonic	LP	DC	data	from	HC,	CD	and	UC	patients	(Supplemental	Figure	3)	were	analysed
using	non-parametric	Kruskal-Wallis	ANOVA	with	Dunn’s	multiple	comparisons	test;	*p<0.05.	
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Tables
Table	1.	Clinical	characteristics	of	St	Mark’s	Hospital	colonoscopy	patients	donating	colonic	biopsies
Characteristic Healthy	Control	(HC) Ulcerative	Colitis	(UC) Crohn’s	disease	(CD)
n 27 14 10
Male/Female 11/16 7/7 3/7
Age	at	sampling	 51	(20-77) 47.3	(24-70) 47.2	(21-77)
Inflammation	categories
None
Mayo	1	(mild	disease)
Mayo	2	(moderate	disease)
Mayo	3	(severe	disease)
Perianal	disease
Chronic	obstruction
Terminal	Ileum	resection
	
	
	
4
5
5
0
0
0
0
	
4
3
1
1
0
0
1
IBD	medications	at	sampling
None
Aminosalicylates
Azathioprine/6-mercaptopurine
Buscopan
	
	
	
8
5
1
0
	
5
3
3
1
Non-IBD	medications	at	sampling
Ondansetron
None
	
	
	
	
0
14
	
1
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Table	1.	Demographic	and	clinical	data	analysed	in	Figs	1-5	and	Supplementary	Figs	1-4.	
Patients	were	recruited	over	a	fixed	period	determined	by	ethical	permission,	and	no	data	were
excluded	at	the	end	of	the	study.	Additional	healthy	blood	volunteers	were	recruited	from	hospital
staff	and	visitors.	Ethics	approval	was	obtained	from	the	Health	Research	Authority	UK	and	London
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Brent	Research	Ethics	Committee.	Written	informed	consent	was	received	from	participants	prior	to
inclusion	in	the	study.	
Table	2.	Clinical	characteristics	of	St	Mark’s	Hospital	blood	donors	and	healthy	volunteers
Characteristic Healthy	Control	(HC) Ulcerative	Colitis	(UC) Crohn’s	disease	(CD)
n 17 11 7
Male/Female 7/10 4/7 2/5
Age	at	sampling	 44.3	(17-86) 46	(26-65) 58.6	(23-80)
Inflammation	categories
CRP	(>5)
ESR	(>20)
Faecal	Calprotectin	(>55)
	 	
3
1
2
	
1
0
1
Symptoms	at	sampling
Diverticular	disease
Diversion	colitis
Fistulating	Crohn’s
	 	
1
0
0
	
0
1
1
IBD	medications	at	sampling
None
Aminosalicylates
Azathioprine/6-mercaptopurine
Adalimumab
	 	
9
2
0
0
	
5
1
0
1
Non-IBD	medications	at	sampling
Vitamins	D/D3/	B12/B9
Loperamide
Alendronate
Metformin
Tamoxifen
Simvastatin
None
	 	
1
0
0
1
1
1
10
	
1
1
1
0
0
0
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Table	2.	Demographic	and	clinical	data	analysed	in	Figs	1-5	and	Supplementary	Fig	1-4.	
Table	3.	Clinical	characteristics	of	Norfolk	and	Norwich	University	Hospital	colonoscopy	patients
donating	colonic	biopsies.
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Characteristic Healthy	Control	(HC)
n 4
Male/Female 3/1
Age	at	sampling	 48.5	(39-66)
Table	3.	Demographic	and	clinical	data	analysed	in	Figure	1b	and	Supplementary	Fig	1a.	
Table	4:	Antibodies	used	for	FACS
Antigen Clone Isotype Fluorochrome Supplier
CD3 UCHT1 IgG1,k PE	Cy5 BD	bioscience
CD14 61D3 IgG1,k PE	Cy5 BioRad-Serotec
CD14 M5E2 IgG2a,k PerCP	Cy5.5 BD	bioscience
CD14 MФP9 IgG2b,k PECF594 BD	Horizon
CD16 3G8 IgG1,k PE	Cy5 BD	bioscience
CD19 HIB19 IgG1,k PE	Cy5 BD	bioscience
CD34 581 IgG1,k PE	Cy5 BD	bioscience
CD64 10.1 IgG1,k PerCP	Cy5.5 BD	bioscience
CD64 10.1 IgG1,k PE	Cy5 Abcam
CD123 6H6 IgG1,k PE	Cy7 eBioscience
HLA-DR G46-6 IgG2a APC BD	bioscience
HLA-DR L234 IgG2a BV421 Biolegend
HLA-DR L234 IgG2a BV570 Biolegend
CD11c B-Ly6 IgG1,k BV605 BD	bioscience
CD40 LOB7/6 IgG2a FITC AbD	Serotec	(Bio-Rad)
CD40 5C3 IgG1 BV711 BD	bioscience
CD45 H130 IgG1,k BUV395 BD	horizon
CD80 L307.4 IgG1,k FITC BD	bioscience
CD80 L307.4 IgG1,k PE BD	bioscience
CD86 BU63 IgG1 FITC AbD	Serotec	(Bio-Rad)
CD86 2331(FUN-1) IgG1,k AlexaFluor700 BD	Pharmingen
CD103	(Integrin	αE) Ber-Act8 IgG1,k BV421 Biolegend,	BD	bioscience
IL-6 MQ2-13A5 IgG1,k	Rat FITC Biolegend
IL-6 MQ2-13A5 IgG1,k	Rat PE eBioscience
IL-10 JES-19F1 IgG1,k	Rat PE Biolegend
IL-10 JES-19F1 IgG1,k	Rat APC BD	bioscience/Biolegend
Integrin	β7 FIB504 IgG2a,	Rat PE Biolegend
Integrin	β7 FIB504 IgG2a,	Rat FITC Biolegend
Integrin	β7 FIB504 IgG2a,	Rat APC BD	bioscience
SIRPα	(CD172a/b) SE5A5 IgG1,k PECy7 Biolegend
Table	4.	List	of	all	antibodies	used	to	identify	and	characterise	human	DC	in	circulation	and	in	colon
for	Figs	1-5	and	Supplementary	Figs	1-2.	
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Figure	1
Bt	OMVs	stimulate	production	of	immunoregulatory	IL-10	from	whole	colonic	biopsies	and
colonic	LP	DC.	During	normal	anaerobic	growth,	Bt	cells	produce	and	release	OMVs	into	the
external	milieu.	a)	Electron	microscope	photograph	of	OMVs	collected	by	sterile	filtration	of
Bt	culture	supernatants	through	0.22	µm	membranes.	Red	arrows	point	to	spherical
nanostructures	consisting	of	lipid	bilayer.	Scale	bar,	~100	nm.	Colonic	biopsies	taken	from
the	rectosigmoid	junction	of	healthy	individuals	were	grown	in	a	pIVOC	system	mucosal	side
up	within	Snapwell	inserts	for	6	h	in	IVOC	medium	with	or	without	108-109	Bt	OMVs.	b)
Following	culture,	biopsies	were	snap-frozen	and	cytokines	and	chemokines	were	measured
within	tissue	homogenates	by	LEGENDplex	cytokine	bead	array.	Amounts	of	MCP-1,	IFN-γ,
IL-8,	IL-1β,	IL-6	and	IL-10shown	are	mean SEM	values	from	n	=	4	healthy	controls	with	two
experimental	replicates	each.	Statistical	significance	was	determined	using	nonparametric
Mann	Whitney	U	tests;	*	p<0.05;	**	p<0.01;	***	p<0.001.	Five	biopsies	each	from	proximal
and	distal	colon	of	healthy	individuals	were	washed	with	DTT/EDTA	and	digested	with
collagenase/liberase	to	obtain	total	LP	cells.	Cells	were	then	cultured	for	20	h	in	the
presence	of	either	killed	107	Bt/mL	or	1010	Bt	OMV/mL	in	complete	RPMI	medium	and	mDC
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were	examined	by	flow	cytometry.	c)	Identification	of	mDC	within	the	total	LP	cells.	d)	Mean
fluorescence	intensity	of	HLA-DR	on	total	mDC	in	response	to	medium	only,	Bt	or	Bt	OMVs.
Statistical	significance	was	determined	by	one-way	ANOVA	with	Dunnett’s	multiple
comparisons	test;	*	p<0.05.	e)	Proportion	of	mDC	expressing	IL-6	(top	panel)	and	IL-10
(bottom	panel)	within	the	colonic	LP.	Pooled	data	from	n=6	HC.	Statistical	significance	was
determined	using	non-parametric	Kruskal-Wallis	ANOVA	with	Dunn’s	multiple	comparisons
test;	*	p<0.05.
Figure	2
Bt	OMVs	stimulate	production	of	immunoregulatory	IL-10	from	whole	colonic	biopsies	and
colonic	LP	DC.	During	normal	anaerobic	growth,	Bt	cells	produce	and	release	OMVs	into	the
external	milieu.	a)	Electron	microscope	photograph	of	OMVs	collected	by	sterile	filtration	of
Bt	culture	supernatants	through	0.22	µm	membranes.	Red	arrows	point	to	spherical
nanostructures	consisting	of	lipid	bilayer.	Scale	bar,	~100	nm.	Colonic	biopsies	taken	from
the	rectosigmoid	junction	of	healthy	individuals	were	grown	in	a	pIVOC	system	mucosal	side
up	within	Snapwell	inserts	for	6	h	in	IVOC	medium	with	or	without	108-109	Bt	OMVs.	b)
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Following	culture,	biopsies	were	snap-frozen	and	cytokines	and	chemokines	were	measured
within	tissue	homogenates	by	LEGENDplex	cytokine	bead	array.	Amounts	of	MCP-1,	IFN-γ,
IL-8,	IL-1β,	IL-6	and	IL-10shown	are	mean SEM	values	from	n	=	4	healthy	controls	with	two
experimental	replicates	each.	Statistical	significance	was	determined	using	nonparametric
Mann	Whitney	U	tests;	*	p<0.05;	**	p<0.01;	***	p<0.001.	Five	biopsies	each	from	proximal
and	distal	colon	of	healthy	individuals	were	washed	with	DTT/EDTA	and	digested	with
collagenase/liberase	to	obtain	total	LP	cells.	Cells	were	then	cultured	for	20	h	in	the
presence	of	either	killed	107	Bt/mL	or	1010	Bt	OMV/mL	in	complete	RPMI	medium	and	mDC
were	examined	by	flow	cytometry.	c)	Identification	of	mDC	within	the	total	LP	cells.	d)	Mean
fluorescence	intensity	of	HLA-DR	on	total	mDC	in	response	to	medium	only,	Bt	or	Bt	OMVs.
Statistical	significance	was	determined	by	one-way	ANOVA	with	Dunnett’s	multiple
comparisons	test;	*	p<0.05.	e)	Proportion	of	mDC	expressing	IL-6	(top	panel)	and	IL-10
(bottom	panel)	within	the	colonic	LP.	Pooled	data	from	n=6	HC.	Statistical	significance	was
determined	using	non-parametric	Kruskal-Wallis	ANOVA	with	Dunn’s	multiple	comparisons
test;	*	p<0.05.
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Figure	3
Lack	of	IL-10	response	from	colonic	DC	to	Bt	OMVs	in	ulcerative	colitis.	Following	20	h
culture	of	LP	cells	from	five	proximal	and	five	distal	colon	biopsies	from	UC	patients	with	Bt
OMVs	1010/mL	or	medium	only,	DC	cytokine	responses	were	examined	by	FACS.	a)	Pooled
data	(n=3)	showing	proportions	of	mDC	expressing	IL-6	(top	left)	and	IL-10	(top	right)	and
representative	FACS	plots	from	one	UC	patient	(bottom).	b)	Comparison	of	proportions	of
mDC	expressing	IL-6	(top)	and	IL-10	(bottom)	in	UC	(n=3)	to	HC	(n=6).	Statistical
significance	was	determined	using	unpaired	t	tests;	*p<0.05.
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Figure	4
Loss	of	immunoregulatory	IL-10	response	by	circulating	DC	to	Bt	OMVs	in	CD	and	UC.	Whole
PBMC	were	separated	from	blood	of	individuals	with	inactive	Crohn’s	Disease	(CD)	or
inactive	or	active	ulcerative	colitis	(UC)	and	intracellular	cytokine	analysis	of	mDC	was
examined	by	FACS.	a)	Pooled	data	from	inactive	UC	(n=5)	and	CD	(n=	5)	patients	show
proportions	of	mDC	expressing	(a)	IL-6	in	response	to	Bt	and	Bt	OMVs	and	compared	to	HC.
b)	Pooled	data	from	inactive	UC	(n=5)	show	proportions	of	mDC	expressing	IL-10	in
response	to	Bt	and	Bt	OMVs	and	compared	to	HC.	c)	Pooled	data	from	inactive	CD	(n=5)
show	proportions	of	mDC	expressing	IL-10	in	response	to	Bt	and	Bt	OMVs	and	compared	to
HC.	Statistical	significance	was	determined	by	Brown-Forsythe	and	Welch	ANOVA	for
unequal	variance	with	Dunnett’s	T3	multiple	comparisons	test	or	two-way	ANOVA	with	Holm
Sidak’s	multiple	comparisons	test;	*p<0.05,	**	p<0.01,	***	p<0.001.	d)	Pooled	data	from
active	UC	(n=3)	showing	proportions	of	mDC	expressing	IL-6	(top)	or	IL-10	(bottom)	and
comparison	to	HC.	Statistical	significance	was	determined	by	non-parametric	Kruskal-Wallis
ANOVA	with	Dunn’s	multiple	comparison	test;	*p<0.05.
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Figure	5
Normal	IL-10	response	to	other	commensal	bacterial	species	or	OMVs	in	inactive	UC.	Whole
PBMC	from	healthy	individuals	(n=4)	or	individuals	with	inactive	UC	(n=3)	were	cultured	for
20	h	in	the	presence	of	19	species	of	killed	commensal	bacteria.	a)	Pooled	data	showing
proportions	of	mDC	expressing	IL-10	are	shown	as	mean	(+/-	SEM).	PBMC	from	healthy
individuals	(HC,	n=4-5)	or	inactive	UC	patients	(n=3)	were	cultured	for	20	h	in	the	presence
of	Pn	and	Pn	OMVs	at	varying	concentrations.	b)	The	proportion	of	mDC	expressing	IL-6	or
IL-10	from	HC	is	shown.	c)	Proportions	of	mDC	expressing	IL-6	(top)	and	IL-10	(bottom)	from
inactive	UC	and	compared	to	HC	are	shown.	Statistical	significance	was	determined	by
ordinary	one-way	ANOVA	with	Dunnett’s	multiple	comparisons	test	or	two-way	ANOVA	with
Holm	Sidak’s	multiple	comparisons	test;	****	p<0.0001.
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